Related Experiment Video
Updated: May 29, 2026

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155
Suhwan Chang1, Rui-Hong Wang, Keiko Akagi
1Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA.
Abstract:
BRCA1, a well-known tumor suppressor with multiple interacting partners, is predicted to have diverse biological functions. However, so far its only well-established role is in the repair of damaged DNA and cell cycle regulation. In this regard, the etiopathological study of low-penetrant variants of BRCA1 provides an opportunity to uncover its other physiologically important functions. Using this rationale, we studied the R1699Q variant of BRCA1, a potentially moderate-risk variant, and found that it does not impair DNA damage repair but abrogates the repression of microRNA-155 (miR-155), a bona fide oncomir. Mechanistically, we found that BRCA1 epigenetically represses miR-155 expression via its association with HDAC2, which deacetylates histones H2A and H3 on the miR-155 promoter. We show that overexpression of miR-155 accelerates but the knockdown of miR-155 attenuates the growth of tumor cell lines in vivo. Our findings demonstrate a new mode of tumor suppression by BRCA1 and suggest that miR-155 is a potential therapeutic target for BRCA1-deficient tumors.
Insights
The BRCA1 tumor suppressor normally represses miR-155, an oncomir. A moderate-risk BRCA1 variant (R1699Q) abrogates this repression, suggesting miR-155 as a therapeutic target for BRCA1-deficient tumors.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- BRCA1 is a tumor suppressor primarily known for DNA repair and cell cycle regulation.
- Investigating low-penetrant BRCA1 variants can reveal novel physiological functions.
- MicroRNA-155 (miR-155) is an oncomir implicated in cancer development.
Purpose of the Study:
- To investigate the functional impact of the moderate-risk BRCA1 R1699Q variant.
- To explore the relationship between BRCA1 and miR-155 expression.
- To elucidate the mechanism of BRCA1-mediated repression of miR-155.
Main Methods:
- Studied the BRCA1 R1699Q variant in cell lines.
- Assessed DNA damage repair capacity.
- Investigated BRCA1's interaction with HDAC2 and its effect on miR-155 promoter.
- Performed in vivo tumor cell growth assays with miR-155 overexpression and knockdown.
Main Results:
- The BRCA1 R1699Q variant does not impair DNA damage repair.
- BRCA1 R1699Q abrogates the repression of miR-155.
- BRCA1 epigenetically represses miR-155 via HDAC2-mediated deacetylation of histones on the miR-155 promoter.
- miR-155 overexpression accelerates tumor cell growth, while knockdown attenuates it.
Conclusions:
- BRCA1 exhibits a novel tumor suppressive function through epigenetic repression of miR-155.
- The R1699Q variant disrupts this function, highlighting its oncogenic potential.
- miR-155 is a potential therapeutic target for BRCA1-deficient tumors.
Related Concept Videos
MicroRNAs
MicroRNAs
MicroRNAs
Abnormal Proliferation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
